STAT+: Relay Therapeutics touts data on bile cancer drug

Relay Therapeutics will present data at a medical meeting Friday that give investors and oncologists the first look at RLY-4008, its drug to treat a form of liver cancer.

“So far in the clinic, 4008 has done everything we designed it to do from the outset,” Don Bergstrom, Relay’s chief medical officer, told STAT.

Relay uses a supercomputer designed at the research firm run by hedge fund billionaire David E. Shaw to better understand proteins and design drugs that target them. The company has a market capitalization of $2.4 billion. 

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Relay Therapeutics touts data on bile cancer drug »